What question did this study set out to answer?

This research aims to evaluate the long-term disability outcomes associated with different therapies for relapsing-onset multiple sclerosis.

April 3, 2026Journal of Neurology1 citationsOpen Access

Long-term disability after initiation of platform versus high-efficacy disease-modifying therapy in relapsing-onset multiple sclerosis

JGJie Guo TOTomas Olsson EJEva Johansson

Key Points

This research aims to evaluate the long-term disability outcomes associated with different therapies for relapsing-onset multiple sclerosis.
Comparison of platform versus high-efficacy disease-modifying therapies
Evaluation of inflammatory and relapse-independent disability components
Long-term follow-up of disability progression
Differential responses observed in inflammatory and relapse-independent disability components
Support for the need of neuroprotective strategies alongside current therapies

Abstract

Our findings suggest that inflammatory and relapse-independent components of MS disability respond differently to current therapies and highlight the need for complementary neuroprotective strategies.

AI에게 질문

Bookmark

View Full Paper